RBC Capital raised the firm’s price target on Beam Therapeutics to $35 from $27 and keeps a Sector Perform rating on the shares after its Q4 results. The company successfully dosed and achieved engraftment with the first Sickle Cell Diseasepatient in Q4 and remains on track to complete sentinel dosing/begin dose expansion in the first half of the year, with first look at data expected in the second half, the analyst tells investors in a research note. RBC notes it is updating its model to reflect a more favorable regulatory environment for Sickle Cell Disease and the addition of GSD1a.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BEAM:
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics reports Q4 EPS $1.73, consensus ($1.01)
- Beam Therapeutics, Inc. (BEAM) Q4 Earnings Cheat Sheet
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference